Literature DB >> 16507407

CD24 and human carcinoma: tumor biological aspects.

S C Lim1.   

Abstract

CD24 is a mucin-like adhesion molecule that has recently raised attention and lent substantial improvements for our understanding of tumor biology. Functionally, CD24 enhances the metastatic potential of malignant-cells, because it has been identified as a ligand of P-selectin, an adhesion receptor on activated endothelial cells and platelets. Moreover, it has been described as a diagnostic molecular marker of malignant tumor and for patient prognosis. This article reviews the experimental and clinical data on CD24 expression and carcinomas from the point of view of tumor biology. Based on the research, CD24 expression will be analyzed as a potentially significant parameter for a wide variety of human cancer diagnoses. Understanding the functions and implications CD24 might aid the clinician in the selection of an appropriate therapy for individual patients: for example, the intravenous administration of C1324-specific antibodies to treat cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16507407     DOI: 10.1016/s0753-3322(05)80076-9

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  43 in total

1.  Sorting mouse jejunal epithelial cells with CD24 yields a population with characteristics of intestinal stem cells.

Authors:  Richard J von Furstenberg; Ajay S Gulati; Anand Baxi; Jason M Doherty; Thaddeus S Stappenbeck; Adam D Gracz; Scott T Magness; Susan J Henning
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-23       Impact factor: 4.052

2.  CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.

Authors:  Sibel Bektas; Burak Bahadir; Bulent Hamdi Ucan; Sukru Oguz Ozdamar
Journal:  Pathol Oncol Res       Date:  2010-02-23       Impact factor: 3.201

3.  CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.

Authors:  Alexandra Winkler; Richard Zigeuner; Peter Rehak; Georg Hutterer; Thomas Chromecki; Cord Langner
Journal:  Virchows Arch       Date:  2006-11-17       Impact factor: 4.064

Review 4.  Cancer stem cells as a potential therapeutic target in breast cancer.

Authors:  Mingzhi Zhang; Zhaoming Li; Xudong Zhang; Yu Chang
Journal:  Stem Cell Investig       Date:  2014-07-16

Review 5.  Associations between CD24 gene polymorphisms and inflammatory bowel disease: A meta-analysis.

Authors:  Xiao-Li Huang; Dong-Hua Xu; Guo-Pin Wang; Shu Zhang; Cheng-Gong Yu
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

Review 6.  Gastrointestinal stem cells in self-renewal and cancer.

Authors:  S Adelia Lin; Nick Barker
Journal:  J Gastroenterol       Date:  2011-07-05       Impact factor: 7.527

7.  Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin.

Authors:  Ja Hye Myung; Khyati A Gajjar; Ryan M Pearson; Cari A Launiere; David T Eddington; Seungpyo Hong
Journal:  Anal Chem       Date:  2011-01-05       Impact factor: 6.986

8.  Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Authors:  Beatriz Mínguez; Yujin Hoshida; Augusto Villanueva; Sara Toffanin; Laia Cabellos; Swan Thung; John Mandeli; Daniela Sia; Craig April; Jian-Bing Fan; Anja Lachenmayer; Radoslav Savic; Sasan Roayaie; Vincenzo Mazzaferro; Jordi Bruix; Myron Schwartz; Scott L Friedman; Josep M Llovet
Journal:  J Hepatol       Date:  2011-04-13       Impact factor: 25.083

9.  CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.

Authors:  Agnieszka Adamczyk; Joanna A Niemiec; Aleksandra Ambicka; Anna Mucha-Małecka; Jerzy Mituś; Janusz Ryś
Journal:  J Mol Histol       Date:  2013-07-09       Impact factor: 2.611

10.  Characterization of human breast cancer epithelial cells (HBCEC) derived from long term cultured biopsies.

Authors:  Ralf Hass; Catharina Bertram
Journal:  J Exp Clin Cancer Res       Date:  2009-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.